



## Research on Pharmacotherapy of Metabolic-Associated Fatty Liver Disease

Guest Editor:

### Dr. Aleksandra Bołdys

Department of Internal Medicine  
and Clinical Pharmacology,  
Medical University of Silesia,  
Medykow 18, 40-752 Katowice,  
Poland

Deadline for manuscript  
submissions:

**30 September 2024**

### Message from the Guest Editor

Dear Colleagues,

This special issue will delve into liver diseases, specifically focusing on the pharmacotherapy of Metabolic-Associated Fatty Liver Disease (MAFLD). Encompassing viral infections and metabolic disorders falling (after nomenclature change in June 2023 during EASL conference) under the umbrella term SLD (Steatotic Liver Disease), including Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) and Metabolic Alcohol-Related Liver Disease or Drug-Induced Liver Injury (DILI), it highlights the crucial role of metabolomics in understanding liver conditions. Authors are encouraged to investigate disruptions in both endogenous and exogenous metabolites, utilizing advanced techniques like lipidomics, cheminformatics, and computational chemistry. The issue underscores the significance of metabolomics in offering insights for early diagnosis, steering targeted therapies, and cultivating a profound understanding of metabolic dysregulation in hepatic disorders.

Dr. Bołdys  
*Guest Editor*





an Open Access Journal by MDPI

## Editor-in-Chief

### Dr. Amedeo Lonardo

1. Formerly Director of the Simple Operating Unit "Metabolic Syndrome", Azienda Ospedaliero-Universitaria, 41126 Modena, Italy  
2. Formerly Professor of Internal Medicine, School of Specialization of Allergy and Clinical Immunology, University of Modena and Reggio Emilia, 41121 Modena, Italy

## Message from the Editor-in-Chief

The metabolome is the result of the combined effects of genetic and environmental influences on metabolic processes. Metabolomic studies can provide a global view of metabolism and thereby improve our understanding of the underlying biology. Advances in metabolomic technologies have shown utility for elucidating mechanisms which underlie fundamental biological processes including disease pathology. *Metabolites* is proud to be part of the development of metabolomics and we look forward to working with many of you to publish high quality metabolomic studies.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPUS / SciFinder, and other databases.

**Journal Rank:** JCR - Q2 (*Biochemistry & Molecular Biology*) / CiteScore - Q2 (*Endocrinology, Diabetes and Metabolism*)

## Contact Us

Metabolites Editorial Office  
MDPI, St. Alban-Anlage 66  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/metabolites](http://mdpi.com/journal/metabolites)  
[metabolites@mdpi.com](mailto:metabolites@mdpi.com)  
X@MetabolitesMDPI